Skip to main content
. 2023 May 23;13(9):3583–3597. doi: 10.1016/j.apsb.2023.05.023

Figure 3.

Figure 3

Bispecific antibodies in cancer therapy would be classified into four categories based on mechanism and target selection. (A) BsAbs that bridge immune effector cells to tumor cells, including pan T cells, γδ T cells and NK (natural killer) cells, etc. (B) BsAbs that bridge receptors from the same or different cells. (C) BsAbs that bridge cytokines and receptors. (D) BsAbs that bridge two cytokines.